Ascendis Pharma AS (ASND)
125.61
+0.33
(+0.26%)
USD |
NASDAQ |
Nov 04, 16:00
125.66
+0.06
(+0.04%)
After-Hours: 20:00
Ascendis Pharma Enterprise Value: 7.950B for Nov. 4, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 04, 2024 | 7.950B |
| November 01, 2024 | 7.930B |
| October 31, 2024 | 7.783B |
| October 30, 2024 | 7.782B |
| October 29, 2024 | 8.020B |
| October 28, 2024 | 8.179B |
| October 25, 2024 | 8.232B |
| October 24, 2024 | 8.201B |
| October 23, 2024 | 8.075B |
| October 22, 2024 | 8.157B |
| October 21, 2024 | 8.132B |
| October 18, 2024 | 8.207B |
| October 17, 2024 | 8.013B |
| October 16, 2024 | 8.231B |
| October 15, 2024 | 8.051B |
| October 14, 2024 | 8.121B |
| October 11, 2024 | 8.145B |
| October 10, 2024 | 8.232B |
| October 09, 2024 | 8.171B |
| October 08, 2024 | 8.335B |
| October 07, 2024 | 8.759B |
| October 04, 2024 | 8.970B |
| October 03, 2024 | 8.867B |
| October 02, 2024 | 9.186B |
| October 01, 2024 | 9.205B |
| Date | Value |
|---|---|
| September 30, 2024 | 9.367B |
| September 27, 2024 | 9.086B |
| September 26, 2024 | 9.234B |
| September 25, 2024 | 9.169B |
| September 24, 2024 | 9.086B |
| September 23, 2024 | 9.188B |
| September 20, 2024 | 9.119B |
| September 19, 2024 | 9.243B |
| September 18, 2024 | 8.982B |
| September 17, 2024 | 8.851B |
| September 16, 2024 | 8.448B |
| September 13, 2024 | 7.281B |
| September 12, 2024 | 6.971B |
| September 11, 2024 | 6.920B |
| September 10, 2024 | 7.025B |
| September 09, 2024 | 7.144B |
| September 06, 2024 | 7.277B |
| September 05, 2024 | 7.268B |
| September 04, 2024 | 7.297B |
| September 03, 2024 | 8.168B |
| August 30, 2024 | 8.384B |
| August 29, 2024 | 8.355B |
| August 28, 2024 | 8.410B |
| August 27, 2024 | 8.403B |
| August 26, 2024 | 8.388B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
3.265B
Minimum
May 11 2022
9.367B
Maximum
Sep 30 2024
6.429B
Average
6.306B
Median
Feb 17 2023
Enterprise Value Benchmarks
| Evaxion Biotech AS | 10.15M |
| Adaptimmune Therapeutics PLC | 18.55M |
| Biodexa Pharmaceuticals PLC | -2.612M |
| NuCana PLC | -11.24M |
| Genfit SA | 288.04M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -117.77M |
| Revenue (Quarterly) | 38.76M |
| Total Expenses (Quarterly) | 182.25M |
| EPS Diluted (Quarterly) | -2.057 |
| Gross Profit Margin (Quarterly) | 68.15% |
| Profit Margin (Quarterly) | -303.9% |
| Earnings Yield | -7.44% |
| Normalized Earnings Yield | -7.443 |